Biosimilar Strength vs. Potency: Avoiding a Regulatory Hobson’s Choice

Biosimilar Strength vs. Potency: Avoiding a Regulatory Hobson’s Choice

Biosimilars bring lower costs and greater access to the market for biological products, but FDA must determine a predicta...  Read more

Waiving COVID-19 Vaccine Patents: A Bad Idea and a Dangerous Precedent

Waiving COVID-19 Vaccine Patents: A Bad Idea and a Dangerous Precedent

Waiving patent protection discourages cutting-edge research investments, which in turn produce breakthrough treatments no...  Read more

'I'm hopeful for the future': Alzheimer's drug approved by FDA

'I'm hopeful for the future': Alzheimer's drug approved by FDA

Peter Pitts of CMPI and Dr. Ronald Petersen of the Mayo Clinic discuss the FDA's approval of aducanumab...  Read more

CMPI

The Center for Medicine in the Public Interest is a nonprofit, nonpartisan research and educational organization that seeks to advance the discussion and development of patient-centered health care.

SUBSCRIBE

VIDEOS & INTERVIEWS

Reports

Research Issues